Evaluation of PI3K/AKT/mTOR Signaling Pathway Using BKM120 in Early Breast Cancer

Trial Profile

Evaluation of PI3K/AKT/mTOR Signaling Pathway Using BKM120 in Early Breast Cancer

Completed
Phase of Trial: Phase 0

Latest Information Update: 30 May 2014

At a glance

  • Drugs Buparlisib (Primary)
  • Indications Early breast cancer
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Apr 2014 According to ClinicalTrials.gov record, the drug BEZ235 is removed from the trial, the trial now has a single treatment arm.
    • 01 Apr 2014 Status changed from recruiting to completed, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top